{"url":"https://lda.senate.gov/api/v1/filings/9fc80d7f-dbd9-4db3-8909-c9283aebaeaa/","filing_uuid":"9fc80d7f-dbd9-4db3-8909-c9283aebaeaa","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2020,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/9fc80d7f-dbd9-4db3-8909-c9283aebaeaa/print/","filing_document_content_type":"text/html","income":null,"expenses":"220000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Jennie Unger Skelton","dt_posted":"2021-01-19T19:04:04.027000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"c/o Politicom Law LLP","registrant_address_2":"28 Liberty Ship Way, Suite 2815","registrant_different_address":false,"registrant_city":"Sausalito","registrant_state":"CA","registrant_zip":"94965","registrant":{"id":401104658,"url":"https://lda.senate.gov/api/v1/registrants/401104658/","house_registrant_id":null,"name":"GREENWICH BIOSCIENCES, INC.","description":"Pharmaceuticals","address_1":"c/o Politicom Law LLP","address_2":"28 Liberty Ship Way, Suite 2815","address_3":null,"address_4":null,"city":"Sausalito","state":"CA","state_display":"California","zip":"94965","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE UNGER SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2022-04-06T16:08:35.323538-04:00"},"client":{"id":202256,"url":"https://lda.senate.gov/api/v1/clients/202256/","client_id":12,"name":"GREENWICH BIOSCIENCES, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-11-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY2021 Approps  (Provisions related to patient safety, product regulations, and FDA enforcement)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69883,"prefix":null,"prefix_display":null,"first_name":"DEBORAH","nickname":null,"middle_name":"LYNN","last_name":"WALTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FDA guidance on CBD enforcement discretion","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69883,"prefix":null,"prefix_display":null,"first_name":"DEBORAH","nickname":null,"middle_name":"LYNN","last_name":"WALTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}